158562-98-2

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Thiazolidinedione, 5-[[4-[2-(methylamino)ethoxy]phenyl]methyl]is used as an antidiabetic drug for managing type 2 diabetes. It is employed to improve insulin sensitivity, thereby helping patients control their blood sugar levels more effectively.
Additionally, it is worth noting that pioglitazone is often used in combination with other medications to achieve better diabetes management. However, due to its association with certain side effects such as an increased risk of bladder cancer and heart failure, its use should be carefully monitored by healthcare professionals to ensure patient safety and optimal treatment outcomes.

Upstream product

• 142649-87-4 phenylmethyl <2-(4-formylphenoxy)ethyl>methylcarbamate 
• 901120-42-1 (Z)-phenylmethyl <2-<4-<(2,4-dioxo-5-thiazolidinylidene)methyl>phenoxy>ethyl>methylcarbamate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 905990-90-1 tert-butyl (2-{4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy}ethyl)methylcarbamate 
• 198990-10-2 tert-butyl (2-(4-formylphenoxy)ethyl)(methyl)carbamate 
• 198990-14-6 tert-butyl (2-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)methylcarbamate 
• 142649-75-0 phenylmethyl <2-<4-<(2,4-dioxo-5-thiazolidinyl)methyl>phenoxy>ethyl>methylcarbamate 

Downstream Products

• 122320-46-1 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione 
• 292615-76-0 N-(2-{4-[2,4-dioxo(1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)-5-(1,2-dithiolan-3-yl)-N-methylpentanamide 
• 463927-89-1 C₂₃H₃₂N₂O₄S 

Relevant academic research and scientific papers

DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR

This invention provides new chemical entities useful for treating a variety of clinical disorders including those that areinfluenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5-adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.

1,2-dithiolane derivatives

This invention provides new thiazolindinedione derivatives and new arylacetic acid derivatives. These compounds are useful for the treatment of cardiovascular diseases, certain endocrine diseases, certain inflammatory diseases, certain neoplastic (maligna

Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPARγ ligands

A library of thiazolidinedione-fatty acid hybrid molecules was designed to probe the relationship between natural and synthetic PPAR ligands. Solid-phase synthesis of the library led to the identification of several high affinity PPARYγ ligands.

benzyl>-2,4-thiazolidinediones as Potent Antihyperglycemic Agents

A series of -2,4-thiazolidinediones and benzyl>-2,4-thiazolidinediones was synthesized from the corresponding aldehydes.Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045).The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies.Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 BI/6 ob/ob mice.From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.